(S)-3-(3-Acetoxy-4-methoxy-phenyl)-2-(benzyloxycarbonyl-methyl-amino)-propionic acid methyl ester | 135226-83-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-3-(3-Acetoxy-4-methoxy-phenyl)-2-(benzyloxycarbonyl-methyl-amino)-propionic acid methyl ester
• 英文别名: methyl (2S)-3-(3-acetyloxy-4-methoxyphenyl)-2-[methyl(phenylmethoxycarbonyl)amino]propanoate
• CAS: 135226-83-4
• 化学式: C₂₂H₂₅NO₇
• 分子量: 415.443
• InChiKey: JAEJCILHLCJYFN-SFHVURJKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.97
• 重原子数：
  30.0
• 可旋转键数：
  8.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  91.37
• 氢给体数：
  0.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  (S)-3-(3-Acetoxy-4-methoxy-phenyl)-2-(benzyloxycarbonyl-methyl-amino)-propionic acid methyl ester 在 palladium on activated charcoal 2,3,5-三甲基吡啶 、 盐酸 、 氢气 、 双(2-氧代-3-恶唑烷基)次磷酰氯 、 sodium hydride 、 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 40.75h， 生成 BOC-D-alanyl-L-alanyl-O4-methyl-L-tyrosyl-L-alanyl-L-tyrosyl-N,O4-dimethyl-L-tyrosine cyclic 54<*>63 ether, methyl ester
  参考文献：
  名称：

  N-Desmethyl Derivatives of Deoxybouvardin and RA-VII: Synthesis and Evaluation

  摘要：

  The synthesis of the complete set of seven N-desmethyl derivatives of RA-VII (8) are described. Thus, the synthesis of the four 14-membered cycloisodityrosine derivatives 21-24 and their coupling with the two tetrapeptides 32 and 33 followed by formation of the 18-membered ring with macrocyclization provided the full set of seven desmethyl derivatives 14-20 of RA-VII (8). The solution phase conformational properties of 8 and 14-20 were examined by 1D and 2D H-1 NMR to reveal the role of N-methylation on the key conformational aspects of the natural agents. In contrast to each of the simple cycloisodityrosine derivatives 21-24 which adopt a single, rigid solution conformation possessing a secondary or tertiary trans amide central to the 14-membered ring, the natural agents including 8 adopt a single predominant solution conformation (83-88%) that corresponds closely to the X-ray structure conformation which possesses an inherently disfavored cis C-30-N-29 tertiary amide central to the 14-membered cycloisodityrosine subunit. Moreover, this cis amide is the predominant conformation (85-95%) observed with N-29-desmethyl RA-VII (14) indicating that even a secondary C-30-N-29 amide adopts this inherently disfavored cis amide stereochemistry. The minor conformation of 8 observed in solution (12-17%) is shown to be derived from a minor cis C-8-N-9 tertiary amide which was not observed with its conversion to a secondary amide. Both N-9-desmethyl RA-VII (15) and N-9,N-29-desmethyl RA-VII (18) adopt exclusively a single solution conformation that corresponds to the major solution conformations of 8 and 14. This conformation contains a characteristic cis C-30-N-29 amide central to a type VI beta-turn and the cycloisodityrosine subunit, a trans C-8-N-9 amide central to a typical type II beta-turn capped with a tight Ala(4)-NH-O=C-Ala(1) hydrogen bond, and a trans C-14-N-15 N-methyl amide. In sharp contrast, removal of the N-15 methyl group within 16, 17, 19, and 20 results in the adoption of solution conformations possessing the inherently favored trans C-30-N-29 amide central to the cycloisodityrosine (14)-membered subunit. Thus, the N-15-methyl group within 8 is responsible for the agents adoption of the disfavored cis C-30-N-29 amide central to the cycloisodityrosine subunit. Importantly, preceding studies have defined the cycloisodityrosine subunit of 8 as the pharmacophore and, in a reversal of the initially assigned roles, revealed that it is the tetrapeptide housed in the 18-membered ring that induces and maintains the rigid, normally inaccessible cis C-30-N-29 amide conformation within the 14-membered cycloisodityrosine subunit. The studies detailed herein reveal that it is the N-15-methyl group that induces this conformational preference for the disfavored cis C-30-N-29 amide and that its removal results in a major conformational change with adoption of the trans C-30-N-29 amide and a loss of biological activity.Thus, the N-15-methyl group is essential for maintenance of the conformational and biological properties of 8; the N-9-methyl group is not essential, and its removal leads to exclusive population of a single biologically active conformation; and the N-29-methyl group once thought essential td the adoption of the C-30-N-29 cis amide is not essential, and its removal does not alter the conformational or biological properties of 8.

  DOI：

  10.1021/ja00133a010
• 作为产物：
  描述：

  3-乙酰基-N-苄氧羰基-L-酪氨酸甲酯 在 间氯过氧苯甲酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 30.0h， 生成 (S)-3-(3-Acetoxy-4-methoxy-phenyl)-2-(benzyloxycarbonyl-methyl-amino)-propionic acid methyl ester
  参考文献：
  名称：

  deoxybouvardin 和 RA-VII 的全合成：通过分子内 Ullmann 反应进行大环化

  摘要：

  我们详细介绍了实施分子内 Ullmann 缩合反应以直接封闭 14 元二芳基醚的成功研究，这些二芳基醚已证明无法通过替代途径或难以通过替代途径获得，以及在 RA-VII 的全合成中使用这种关键的大环化反应和脱氧布瓦丁

  DOI：

  10.1021/ja00004a062

文献信息

• Synthesis of New DOPA Derivative from L-Tyrosine for Construction of Bioactive Compound
  作者：Dequn Sun、Peihong Wan、Guoqing Zhang、Min Luo

  DOI：10.14233/ajchem.2013.14893

  日期：——

  A practical synthetic method of new DOPA derivative was developed with L-tyrosine as starting material. The new DOPA analogue could be used in building bioactive compounds.

  一种以L-酪氨酸为起始原料的新多巴衍生物的实用合成方法被开发出来。这种新的多巴类似物可用于构建生物活性化合物。
• Total synthesis of cycloisodityrosine, RA-VII, deoxybouvardin, and N29-desmethyl-RA-VII: Identification of the pharmacophore and reversal of the subunit functional roles
  作者：Dale L. Boger、Daniel Yohannes、Jiacheng Zhou、Michael A. Patane

  DOI：10.1021/ja00062a004

  日期：1993.5

  Full details of a concise total synthesis of RA-VII (1) and deoxybouvardin (2) are described based on the implementation of an effective intramolecular Ullmann reaction as the key macrocyclization reaction in the preparation of the elusive 14-membered cycloisodityrosine subunit (33) of the bicyclic hexapeptides. Subsequent coupling of 34 to tetrapeptide 17 and macrocyclization with C 2 -N 3 amide bond

  基于有效的分子内 Ullmann 反应作为制备难以捉摸的 14 元环异二酪氨酸亚基 (33) 的关键大环化反应的实施，描述了 RA-VII (1) 和脱氧布瓦丁 (2) 的简明全合成的全部细节的双环六肽。随后 34 与四肽 17 偶联以及大环化与 C 2 -N 3 酰胺键形成提供了 1 和 2。在解决有助于其抗肿瘤活性的药物的关键结构和构象特征的努力中，N 29 -去甲基-RA-制备了 VII 并详细说明了其化学、构象和初步生物学特性
• BOGER, DALE L.;YOHANNES, DANIEL, J. AMER. CHEM. SOC., 113,(1991) N, C. 1427-1429
  作者：BOGER, DALE L.、YOHANNES, DANIEL

  DOI：——

  日期：——